Carlo Cattrini

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

Cancers

Therapeutic advances in urology

Journal of medical virology

Immunotherapy

Centro Nacional de Investigaciones Oncológicas

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Centro Nacional de Investigaciones Oncológicas

Spain

Clinical Fellow :: Prostate Cancer Clinical Research Unit

San Martino Polyclinic Hospital – Institute for Cancer Research and Treatment

Italy

Resident :: Academic Unit of Medical Oncology

Mario Negri Institute for Pharmacological Research

Italy

Researcher (postgraduate research grant) :: Department of Oncology

Publications

Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros K Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica, Anna Patrikidou
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers 16 (8) (2024)
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros K Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica, Anna Patrikidou
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. Cancers 16 (8) (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Sebastiano Buti, Alessandro Olivari, Cristina Masini, Davide Bimbatti, Donata Sartori, Paola Ermacora, Carlo Cattrini, Maria Giuseppa Vitale, Ernesto Rossi, Claudia Mucciarini, Mimma Rizzo, Michele Sisani, Matteo Santoni, Giandomenico Roviello, Veronica Mollica, Vincenza Conteduca, Francesco Grillone, Marika Cinausero, Giuseppe Prati, Francesco Atzori, Marco Stellato, Francesco Massari, Melissa Bersanelli
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients. Therapeutic advances in urology 16 (2024)
Chiara Tommasi, Giulia Scartabellati, Diana Giannarelli, Ugo De Giorgi, Nicole Brighi, Giuseppe Fornarini, Sara Elena Rebuzzi, Silvia Puglisi, Orazio Caffo, Stefania Kinspergher, Alessia Mennitto, Carlo Cattrini, Matteo Santoni, Elena Verzoni, Alessandro Rametta, Marco Stellato, Andrea Malgeri, Giandomenico Roviello, Matteo Brunelli, Sebastiano Buti
The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study. Therapeutic advances in urology 15 (2023)
Carlo Cattrini, Carlo Messina, Alessia Mennitto, Massimo Di Maio, Alessandra Gennari, David Olmos
Comments on "Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476)". International journal of cancer 151 (12) (2022)
Carlo Cattrini, Orazio Caffo, Ugo De Giorgi, Alessia Mennitto, Alessandra Gennari, David Olmos, Elena Castro
Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. Cancers 14 (7) (2022)
Sebastiano Buti, Melissa Bersanelli, Giulia Mazzaschi, Carlo Cattrini, Matteo Brunelli, Massimo Di Maio
Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy (2021)
Giandomenico Roviello, Sebastiano Buti, Carlo Cattrini, Alessia Mennitto, Carlo Messina, Chiara Airoldi, Gianmarco Vannini, Melissa Bersanelli
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? Therapeutic advances in urology 13 (2021)
Carlo Cattrini, Carlo Messina, Chiara Airoldi, Sebastiano Buti, Giandomenico Roviello, Alessia Mennitto, Orazio Caffo, Alessandra Gennari, Melissa Bersanelli
Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis. Therapeutic advances in urology 13 (2021)
Paolo Pedrazzoli, David Rondonotti, Carlo Cattrini, Simona Secondino, Paolo Ravanini, Antonio Piralla, Pier Paolo Sainaghi, Diego Brustia, Cristina Bozzola, Marisa Gariglio, Christian Cossandi, Giovanni Rosti, Alessandra Gennari
Metastatic Mediastinal Germ-Cell Tumor and Concurrent COVID-19: When Chemotherapy Is Not Deferrable. The oncologist 26 (2) (2021)
Federica Biello, Francesca Platini, Francesca D'Avanzo, Carlo Cattrini, Alessia Mennitto, Silvia Genestroni, Veronica Martini, Paolo Marzullo, Gianluca Aimaretti, Alessandra Gennari
Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights. Biomolecules 11 (1) (2021)
Carlo Cattrini, Rodrigo España, Alessia Mennitto, Melissa Bersanelli, Elena Castro, David Olmos, David Lorente Estellés, Alessandra Gennari
Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. Cancers 13 (18) (2021)
Cinzia Borgogna, Marco De Andrea, Gloria Griffante, Alessia Lai, Annalisa Bergna, Massimo Galli, Giangluglielmo Zehender, Luigi Castello, Paolo Ravanini, Carlo Cattrini, Alessia Mennitto, Alessandra Gennari, Marisa Gariglio
SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response. Journal of medical virology 93 (12) (2021)
Carlo Cattrini, Melissa Bersanelli, Maria Maddalena Latocca, Benedetta Conte, Giacomo Vallome, Francesco Boccardo
Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer. Cancers 12 (8) (2020)
Carlo Cattrini, Davide Soldato, Alessandra Rubagotti, Linda Zinoli, Elisa Zanardi, Paola Barboro, Carlo Messina, Elena Castro, David Olmos, Francesco Boccardo
Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. Cancers 12 (10) (2020)
Carlo Cattrini, Elena Castro, Rebeca Lozano, Elisa Zanardi, Alessandra Rubagotti, Francesco Boccardo, David Olmos
Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers 11 (9) (2019)
Carlo Cattrini, Alessandra Rubagotti, Linda Zinoli, Luigi Cerbone, Elisa Zanardi, Matteo Capaia, Paola Barboro, Francesco Boccardo
Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients. Cancers 11 (9) (2019)

Carlo Cattrini.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Carlo Cattrini